サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375851

ヒト免疫不全ウイルス治療薬の市場規模、シェア、動向分析レポート：薬剤タイプ別、薬剤クラス別、地域別、セグメント別予測、2023年～2030年

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 75 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ヒト免疫不全ウイルス治療薬の市場規模、シェア、動向分析レポート：薬剤タイプ別、薬剤クラス別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年10月03日
発行: Grand View Research
ページ情報: 英文 75 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒト免疫不全ウイルス治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、ヒト免疫不全ウイルス（HIV）-1治療薬の世界市場規模は、2023年から2030年にかけてCAGR 1.5％で拡大し、2030年には113億4,000万米ドルに達する見込みです。

HIVは世界的に最も課題となっている公衆衛生問題の一つであり続けています。

市場成長を促進する主な要因としては、無防備な性行為、感染した体液や組織で汚染された注射針や注射器への曝露、感染リスク要因に関する認識不足などにより、特に若者の間でHIV感染率が増加していることが挙げられます。英国を拠点とするHIV/エイズ慈善団体AVERTによると、2015年にHIVに罹患した推定患者数は3,500万人以上と記録されています。

HIVは、発展途上国や低開発国、主にアジアやアフリカ地域の人々に大きな影響を与えています。この感染症は現在のところ治癒不可能であるため、抗レトロウイルス療法の主な目的は、作用機序に基づいて6つの異なる薬剤クラスに分類される抗レトロウイルス薬を用いて、患者のウイルス複製を抑制することです。

併用療法では、各クラスがHIVのライフサイクルにおける異なるステップを標的とするため、少なくとも2～3種類の薬剤クラスの薬剤が使用されます。薬剤の組み合わせは、患者の病歴、抗レトロウイルス薬の副作用に対する素因、他の疾患との重複感染などに基づいて選択されます。

ヒト免疫不全ウイルス治療薬市場レポート・ハイライト

  • インテグラーゼ阻害薬セグメントは、Gilead Sciences, In.やMerck &Co., Inc.などの大手企業によるインテグラーゼ阻害薬の追加発売が期待されることから、抗レトロウイルス薬の中で最も急成長するクラスと予想されます。
  • 2022年の市場シェアは、北米が51.5％以上で最大でした。診断施設へのアクセスが容易であることが、この地域の市場拡大を支える主な要因のひとつです。
  • アジア太平洋地域は、医療インフラの充実と成長を後押しする適切な政府施策の存在により、最も急成長している地域セグメントであり、予測期間中もその地位を維持すると予測されています。
  • ギリアド・サイエンシズ社は、市場シェアと薬剤ポートフォリオに関してHIV-1治療薬セクターのリーダーであり、2015年にはヴィーブヘルスケア社がこれに続いた。さらに、今後数年のうちに、他の小規模プレーヤーがパイプライン医薬品でこの分野に参入すると予想されています。
  • この業界の他の重要なプレーヤーには、AbbVie, Inc.、Bristol-Myers Squibb Company、Merck &Co.

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヒト免疫不全ウイルス治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ヒト免疫不全ウイルス治療薬：市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 ヒト免疫不全ウイルス治療薬市場：薬剤タイプの推定・動向分析

  • ヒト免疫不全ウイルス治療薬市場：重要なポイント
  • ヒト免疫不全ウイルス治療薬市場：薬剤タイプの動向と市場シェア分析、2022年および2030年
  • ブランド医薬品
  • ジェネリック医薬品

第5章 ヒト免疫不全ウイルス治療薬市場：薬剤クラスの推定・動向分析

  • ヒト免疫不全ウイルス治療薬市場：重要なポイント
  • ヒト免疫不全ウイルス治療薬市場：医薬品クラスの動向と市場シェア分析、2022年および2030年
  • ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）
  • 非ヌクレオシド逆転写酵素阻害剤（NNRTI）
  • 侵入阻害剤と融合阻害剤
  • プロテアーゼ阻害剤（PI）
  • インテグラーゼ阻害剤
  • コレセプターアンタゴニスト

第6章 ヒト免疫不全ウイルス治療薬市場：地域別の推定・動向分析

  • 地域別の見通し
  • 地域別ヒト免疫不全ウイルス治療薬市場：重要なポイント
  • 北米
    • 北米市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州市場推計・予測、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • アジア太平洋市場推計・予測、2018～2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカ市場推計・予測、2018～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA市場推計・予測、2018年から2030年
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • ViiV Healthcare
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 6 U.S. human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Canada human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 Europe human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Europe human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 UK human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 UK human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 France human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 France human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Italy human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Italy human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Spain human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Spain human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Sweden human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 Sweden human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Norway human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Norway human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Denmark human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Denmark human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 China human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Japan human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Japan human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 India human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 India human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Australia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Australia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Thailand human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Thailand human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 South Korea human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 South Korea human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Latin America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 44 Latin America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Latin America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 47 Brazil human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Mexico human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 49 Mexico human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Argentina human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 Argentina human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 56 South Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 UAE human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 UAE human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Kuwait human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Human immunodeficiency virus therapeutics: Market outlook
  • Fig. 9 Human immunodeficiency virus therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Human immunodeficiency virus therapeutics market driver impact
  • Fig. 15 Human immunodeficiency virus therapeutics market restraint impact
  • Fig. 16 Human immunodeficiency virus therapeutics market strategic initiatives analysis
  • Fig. 17 Human immunodeficiency virus therapeutics market: Drug type movement analysis
  • Fig. 18 Human immunodeficiency virus therapeutics market: Drug type outlook and key takeaways
  • Fig. 19 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Human immunodeficiency virus therapeutics market: Drug class movement analysis
  • Fig. 22 Human immunodeficiency virus therapeutics market: Drug class outlook and key takeaways
  • Fig. 23 Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Entry and fusion inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Protease inhibitors (PIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Integrase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Coreceptor antagonists market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global human immunodeficiency virus therapeutics market: Regional movement analysis
  • Fig. 30 Global human immunodeficiency virus therapeutics market: regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-210-5

Human Immunodeficiency Virus Therapeutics Market Growth & Trends:

The global Human Immunodeficiency Virus (HIV)-1 therapeutics market size is expected to reach USD 11.34 billion by 2030, expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Human Immunodeficiency Virus Therapeutics Market Report Highlights:

  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • North America held the largest market share in 2022 with a share of over 51.5%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug type
    • 1.1.2. Drug class
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Human Immunodeficiency Virus Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Human Immunodeficiency Virus Therapeutics: Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Human Immunodeficiency Virus Therapeutics Market: Drug Type Estimates & Trend Analysis

  • 4.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 4.2. Human Immunodeficiency Virus Therapeutics Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Branded Drugs
    • 4.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Generic Drugs
    • 4.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Human Immunodeficiency Virus Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 5.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 5.2. Human Immunodeficiency Virus Therapeutics Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 5.3.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.4.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Entry and Fusion Inhibitors
    • 5.5.1. Entry and fusion inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Protease Inhibitors (PIs)
    • 5.6.1. Protease inhibitors (PIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Integrase Inhibitors
    • 5.7.1. Integrase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Coreceptor Antagonists
    • 5.8.1. Coreceptor antagonists market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Human Immunodeficiency Virus Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Human Immunodeficiency Virus Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. UK
      • 6.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. France
      • 6.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. China
      • 6.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. India
      • 6.5.4.1. India market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AbbVie Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boehringer Ingelheim International GmbH
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Bristol-Myers Squibb Company
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Cipla Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Genentech, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Gilead Sciences, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co., Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. ViiV Healthcare
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives